Hookipa Net Receivables from 2010 to 2024

HOOK Stock  USD 2.58  0.06  2.38%   
Hookipa Pharma Net Receivables yearly trend continues to be quite stable with very little volatility. The value of Net Receivables is projected to decrease to about 16.4 M. From the period between 2010 and 2024, Hookipa Pharma, Net Receivables regression line of its data series had standard deviation of  6,624,271 and standard deviation of  6,624,271. View All Fundamentals
 
Net Receivables  
First Reported
2018-12-31
Previous Quarter
22.6 M
Current Value
25 M
Quarterly Volatility
7.6 M
 
Covid
Check Hookipa Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hookipa Pharma's main balance sheet or income statement drivers, such as Tax Provision of 454.6 K, Net Interest Income of 4.8 M or Interest Income of 5.2 M, as well as many indicators such as Price To Sales Ratio of 3.61, Dividend Yield of 0.0 or PTB Ratio of 0.81. Hookipa financial statements analysis is a perfect complement when working with Hookipa Pharma Valuation or Volatility modules.
  
Check out the analysis of Hookipa Pharma Correlation against competitors.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

Latest Hookipa Pharma's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Hookipa Pharma over the last few years. It is Hookipa Pharma's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Hookipa Pharma's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Hookipa Net Receivables Regression Statistics

Arithmetic Mean11,086,507
Geometric Mean9,515,638
Coefficient Of Variation59.75
Mean Deviation5,874,542
Median6,520,000
Standard Deviation6,624,271
Sample Variance43.9T
Range17.1M
R-Value0.79
Mean Square Error17.6T
R-Squared0.63
Significance0.0004
Slope1,174,404
Total Sum of Squares614.3T

Hookipa Net Receivables History

202416.4 M
202319.3 M
202222 M
202121.2 M
202020.7 M
20199.7 M
20184.9 M

About Hookipa Pharma Financial Statements

Hookipa Pharma investors utilize fundamental indicators, such as Net Receivables, to predict how Hookipa Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables19.3 M16.4 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:
Check out the analysis of Hookipa Pharma Correlation against competitors.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.67)
Revenue Per Share
4.403
Quarterly Revenue Growth
(0.52)
Return On Assets
(0.20)
Return On Equity
(0.49)
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.